GO
Loading...

NPS Pharmaceuticals Inc

More

  • NPS reports 3Q loss Monday, 10 Nov 2014 | 4:39 PM ET

    BEDMINSTER, N.J. _ NPS Pharmaceuticals Inc. on Monday reported a loss of $2.1 million in its third quarter. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 1 cent per share. Analysts expected $59.9 million, according to Zacks.

  • The FDA also asked the company to submit a Risk Evaluation and Mitigation Strategy for the drug, Natpara. The FDA extension follows an 8-5 vote in favor of the drug's approval by an FDA advisory panel in September. The FDA set Jan. 24 as the review date for the drug.

  • US STOCKS-NPS soars after preliminary review from FDA Wednesday, 10 Sep 2014 | 9:10 AM ET

    NEW YORK, Sept 10- NPS Pharmaceuticals Inc rose sharply in premarket trading on Wednesday, after a preliminary review by the Food and Drug Administration said the company's hormone replacement therapy Natpara reduced the need for calcium and vitamin D supplements in clinical trials.

  • *Shire expecting to receive approaches, taps Citi- sources. LONDON, June 17- Shares in Shire hit a record high on Tuesday on expectations of a takeover as dealmaking sweeps the drugs sector, after Reuters reported the group had hired investment bank Citi as a defence adviser. Shire and Citi declined to comment.

  • Even biotechs blame the weather Thursday, 8 May 2014 | 12:49 PM ET

    It's been a gloomy week for biotech earnings, and many have blamed their poor results on, of all things, the weather.

  • Midday movers: Carnival, Netlfix, Pfizer & More Tuesday, 25 Mar 2014 | 12:10 PM ET
    Carnival Cruise Lines

    Some of Tuesday's midday movers:

  • Lightning Round: Hertz, NPS Pharma & More Wednesday, 11 Dec 2013 | 6:42 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Francois Nader, NPS Pharmaceuticals president & CEO, discusses its lead product Gattex for "short bowel syndrome," the potential for Netpara and the solid performance of its stock.

  • 8 stocks up more than 200% year to date: Cramer Tuesday, 1 Oct 2013 | 6:48 PM ET
    Jim Cramer at MM2K show on Wall Street

    They’re among the best performers in the Russell 2000 and they all share something in common.

  • Lightning Round: Visa, Pandora & More Monday, 30 Sep 2013 | 6:41 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Jim Cramer spec surges 200% in 6 months Wednesday, 11 Sep 2013 | 6:16 PM ET

    Sometimes a spec stock turns out to be more right than even Cramer imagined.

  • NPS Pharma CEO: Do not need to raise cash     Wednesday, 11 Sep 2013 | 6:15 PM ET

    NPS Pharmaceuticals is a developer of orphan drugs for ultra-rare diseases, and its stock has been on a tear for 6 months. Its CEO Dr. Francois Nader discusses its latest trials and FDA approvals.

  • Lightning Round: US Airways, Xerox & More Friday, 31 May 2013 | 6:40 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer: Real Opportunity in This Drug Maker Monday, 7 Jan 2013 | 6:18 PM ET

    "It's speculative, but I think we could have a real opportunity here," said Cramer

  • NPS Pharmaceuticals CEO Dr. Francois Nader discusses the approval of its short bowel syndrome drug Gattex, and what's next for the company.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

    TheStreet.com offers up 13 biotech predictions for 2013.

  • NPS Pharmaceuticals CEO on Orphan Drugs     Wednesday, 24 Oct 2012 | 6:45 PM ET

    NPS Pharmaceuticals president & CEO Dr. Francois Nader, discusses strategies his company uses to finding value for shareholders, and appealing to the FDA.

  • FDA panel votes to support NPS Pharma bowel drug Tuesday, 16 Oct 2012 | 5:03 PM ET

    NEW YORK-- A Food and Drug Administration advisory panel on Tuesday recommended that the FDA approve NPS Pharmaceuticals Inc.' s experimental bowel drug Gattex. The positive recommendation from the Gastrointestinal Drugs Advisory Committee makes it more likely the FDA will approve Gattex, although does not guarantee approval.

  • NPS shares halted as FDA panel reviews bowel drug Tuesday, 16 Oct 2012 | 9:37 AM ET

    NEW YORK-- Trading of NPS Pharmaceuticals Inc. shares was halted Tuesday as a Food and Drug Administration advisory panel began discussing NPS' experimental bowel drug Gattex. NPS will discuss Gattex with the FDA's Gastrointestinal Drugs Advisory Committee. NPS Pharmaceuticals shares trade on the Nasdaq Global Market.

  • NPS Pharma jumps ahead of Gattex FDA review Friday, 12 Oct 2012 | 6:34 PM ET

    NEW YORK-- Shares of NPS Pharmaceuticals Inc. surged to their highest price in more than six years Friday as investors hope that a Food and Drug Administration advisory panel will recommend that the FDA approve NPS' bowel drug Gattex.